CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

Author(s):
Dezentje, V.O.; Opdam, F.L.; Gelderblom, H.; Hartigh, J. den; Straaten, T. van der; Vree, R.; Maartense, E.; Smorenburg, C.H.; Putter, H.; Dieudonne, A.S.; Neven, P.; Velde, C.J.H. van de (0000-0003-0104-1800); Nortier, J.W.R.; Guchelaar, H.J. (0000-0002-7085-1383)
Published
2015
Publication type
Article / Letter to editor
CYP2D6EndoxifenEarly breast cancer
Date issued
2015-10-31
Language
English
Is part of
Breast Cancer Research and Treatment (2015), Vol. 153, no. 3, p. 583-590
hdl
1887/107917
doi
10.1007/s10549-015-3562-5